oldi Tripidm wi colgro h Arri Arrionil (i alolz


Treatment of Type 2 Diabetes Following Sulfunylurea Failure

Secondary failure .() A1c () / ± / . (/ / ± / (/ /)

.(

)

()	()	
-	± /	
-	± /	
-	/ ± /	
-	/ ±	



		(%)			
	()	.,	()	
/ ± /	/ ± /	(/)		_	
/ ± /	/ ±	()		_	
/ ± /	/ ± /	(/)			
/ ± /	/ ± /	()			•
P = /	P = /				

		()		
/ -	/ ±	1 -	±	()
/ - /	/ ± /	_	±	
_	/ ± /	1 -	±	
1 – 1	/ ±	_	± /	
1 -	±	-	/ ± /	

.() .() .() () () .() .() (Multiple MSI NPH (Continuous Subcutaneous Insulin Infusion) CSII Subcutaneous Injections) () .()

www. SID. ir

.() 1 .() / ± / / ± / / ± / .() (Body Mass Index) / ± / / ± / /) .(

Background: Half of the patients with type 2 diabetes have secondary failure to sulfonylurea compounds by 5 years. Emphasis on diet and adding a second drug is not usually effective and Insulin therapy is necessary. This may induce weight gain that is not desirable.

Material and Method: 200 cases of type 2 diabetes with sulfonylurea failure were evaluated at least every 3 months for more than 2 years after insulin therapy. FBS, weight and Body Mass Index (BMI) was measured. This study included 160 female and 40 male patients.

Results: The age of starting sulfonylurea compound was 43±8.9 years. Duration of effectiveness was 9.3± 4.4 years. Interval of unresponsiveness to insulin therapy was 16.9±13.9 months. One year after insulin therapy 32% (64 patients) had acceptable fasting blood glucose (60-139mg/dl) but they had weight gain of 5±3.5 Kg. 45 % (90 patients) had intermediate control (FBS of 140-199 mg/dl) They had 4.9± 3.4 Kg weight gain. 23%(46 patients) remained in poor control state (>200 mg/dl). They had 3.5±3.1 Kg weight gain. 2 years after starting insulin therapy, fasting blood sugar was like the first year but weight gain was more increased.


Conclusion: Sulfonylurea compounds usually loose their effectiveness in few years (in our study 9 years). It is not good to delay insulin therapy (in our study 16.9 months). In spite of near normalization of blood glucose there will be weight gain (more than with ideal control) which is not desirable and should be considered in management of diabetic patients.

Key words: Diabetes, Sulfonylurea failure, Insulin therapy.

REFERENCES

- 1-Alvin C. Powers, Diabetes Mellitus in Harrisons's principles of internal medicine. 15th ed. Vol.2. McGraw Hill,2001,Ch. 333:2109-2137.
- 2-Saul Genuth, MD. Management of the adult onset diabetic with sulfonylurea drug failure. Endocrinology and Metabolism, Clinics of North America, Diabetes Mellitus. Perspectives on therapy. Vol. 21. Number 2. June 1992:351-365.
- 3-Roger H. Unger and Daniel W. Foster. Diabetes Mellitus in Williams text book of endocrinology.9th ed. W.B. Saunders Co. 1998. Ch. 21: 973-1040.
- 4-Harold E. Lebovitz, Oral antidiabetic agents in Goslings Diabetes Mellitus. 13th ed. Lea & Febiger Co. 1994. Ch. 29: 508- 522.
- 5-Christos Zollpas, Olga, Kepaptso Glou. Is the combination of metformine plus insulin the treatment of choice in insulin treated patients with syndrome "X"? 56 th annual meeting and scientific sessions Morscone

- center. Sanfrancisco, California. Diabetes abstract book. 8-11 June 1996. Abstract number 537.
- 6-Jun Kawaki, Kazuaki Nagashima. et al: Unresponsiveness to glibenclamide during chronic treatment induced by reduction of ATP-sensitive K+ channel activity. Diabetes. Vol. 48. October 1999:2001-2006.
- 7-David M, Nathan: Insulin treatment of noninsulin-dependent diabetes mellitus. Ellenberg & Rifkin's Diabetes Mellitus. 5th ed. Appleton & Lang. 1997: 735-741.
- 8-United Kingdom Prospective Diabetes Study Group. A- 6 year randomized, controlled comparing sulfonylurea, insulin and metformine therapy inpatients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Annals of Internal Medicine. Vol. 123. Number 3. Feb 1998:165-174.
- 9-Stein Vaaler. Optimal glycemic control in types 2 diabetic patients: Does including insulin treatment mean a better outcome? Diabetes cares. Vol. 23, Supplement 2, April 2000: B30- B33.
- 10-Takei H, Takayama S, Yamauchi A. et al: Effect of insulin therapy on body fat distribution in NIDDM patients with secondary sulfonylurea failure. 30, Eur. J. Clin. Nut. 1998. Feb: 52(2) 153-4, ISSN: 0954-3007.
- 11-PAT Miles, Pamcox, Joan Everet and David Keer. Insulin treatment in poorly controlled NIDDM. Good idea or bad mistake? 54th Annual meeting and scientific sessions. New Orlean. Diabetes abstract book. February 1994. Abstract number 258.



. (/)

Isulin therapy in type 2 diabetes with Sulfonylurea failure

Azhari P., Rajabian R. Mashhad University of Medical. Sciences

Background: Half of the patients with type 2 diabetes have secondary failure to sulfonylurea compounds by 5 years. Emphasis on diet and adding a second drug is not usually effective and Insulin therapy is necessary. This may induce weight gain, that is not desirable.

Material and method: 200 cases of type 2 diabetes with sulfonylurea failure were evaluated at least every 3 months for more than 2 years after insulin therapy. FBS, weight and body mass index (BMI) was measured. This study included 160 female and 40 male patients.

Results: The age of starting solfonylureal compound was 43 ± 8.9 years. Duration of effectiveness was 9.3 ± 4.4 years. Interval of unresponsiveness to insulin therapy was 16.9 ± 13.9 months. One year after insulin therapy 32% (64 patients) had acceptable fasting blood glucose (60-139mg/dl) but they had weight gain of 5 ± 3.5 Kg. 45% (90 patients) had intermediate control (FBS of 140-199 mg/dl)They had 4.9 ± 3.4 Kg weight gain. 23%(46 patients) remained in poor control state (>200 mg/dl). They had 3.5 ± 3.1 Kg weight gain. 2 years after starting insulin therapy, fasting blood sugar was like the first year but weight gain was more increased. **Conclusion:** Sulfonylurea compounds usually loose their effectiveness in few years (in our study 9 years). It is not good to delay insulin therapy (in our study 16.9months). In spite of near normalization of blood glucose there will be weight gain (more than with ideal control) which is not desirable and should be considered in management of diabetic patients.

